Anlon Healthcare Limited — Q2FY27 earnings call summary

Filed 06 November 2026 · Official transcript

Capacity expansion on track: 1,200 MTPA at Rajkot by Q1 FY28; Apiqo 500-600 MTPA by Q1 FY28
CDMO commercial supply delayed; first molecule expected Q4 FY27; others post H1 FY28
Q2 FY27 consolidated revenue 105.61 Cr (+102.3% y-y), EBITDA 25.24 Cr (+84.1%), PAT 17.18 Cr (+84.4%)
H1 FY27 revenue 193.17 Cr (+125.9%), EBITDA 40.83 Cr (+104.7%, margin 21.1%), PAT 25.46 Cr (+97.9%)
EBITDA margin recovering to 23.9% in Q2; expected sustainable range 25-28%
Medical devices revenue expected from Q3 FY28; EBITDA margin above 25% anticipated
FY27 revenue guidance INR 380-400 Cr; FY28 guidance INR 650-700 Cr
Working capital cycle improved; operating cash flow positive expected by FY27 end